Core 2: A program to train the next generation in cancer drug development
Official title: Core 2: Research Education
Funded at Beckman Research Institute/city of Hope · NIH-11415826 · Data updated 2026-11-12
A partnership program to build training, resources, and curriculum so researchers at UCR and City of Hope can move cancer ideas toward clinical trials and develop future drug developers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $104,846 |
| NIH project number | 5U54CA285116-04 |
| Project ID | NIH-11415826 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are students, fellows, and early-career researchers at UCR or City of Hope who want to work on cancer drug development and clinical trials.
✕Less likely to help
Patients are unlikely to benefit directly from this education core alone, but may benefit indirectly through enhanced future treatments.
What this research studies
This grant creates a coordinated education core to boost cancer drug development at UCR and City of Hope. It will develop curriculum, hands-on experiences, and research resources to translate basic discoveries into therapies and clinical trials, while teaching ethics and HIPAA. Students, postdocs, and early-career investigators will gain exposure to drug development methods and opportunities in clinical research. The program also emphasizes outreach to broaden career opportunities in this field and build local capacity for translational science.
Why it matters
Potential benefit: If successful, patients could benefit from faster translation of promising cancer therapies from lab ideas to clinical trials.
How similar studies have gone: This type of education core has shown to build workforce and readiness for translational research in cancer drug development.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Talisman, Tijana — Beckman Research Institute/city of Hope
- Study coordinator: Talisman, Tijana
Related research
Other NIH-funded projects on the same topics.
-
Targeting the protein-assembly that drives AML growth
Aiming to slow or stop acute myeloid leukemia by blocking how cancer cells make proteins.
-
Metformin for reversing accelerated aging in young adults with metabolic health issues
A practical plan to use metformin to help 18- to 35-year-olds with insulin resistance improve metabolic health and slow aging.
-
PIN1-targeted therapy for pancreatic cancer
A team is developing new PIN1 inhibitors to treat pancreatic cancer that tends to resist current therapies.
-
DNA mismatch repair defects and anti-tumor immunity in cancer
Researchers are studying how defects in a DNA repair system affect the body’s immune response to tumors, to improve cancer treatments that use the immune system.
-
Understanding how skin cancer-associated fibroblasts affect immune detection in early mycosis fungoides
This grant investigates how certain skin cells in early mycosis fungoides might help the cancer hide from the immune system, with findings aiming to improve future patient care.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.